This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation

Title Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation
Abstract

Multitarget ligands (MTLs) have emerged as an interesting alternative for addressing complex multifactorial pathologies such as neurodegenerative diseases. However, a common challenge associated with these compounds is often their high molecular weight and low solubility, which becomes a hurdle when trying to permeate over the blood-brain barrier (BBB). In this study, we have designed two new MTLs that modulate three pharmacological targets simultaneously (tau, beta-amyloid and TAR DNA-binding protein 43). To enhance their brain penetration, we have formulated organic polymeric nanoparticles using poly(lactic-co-glycolic acid). The characterization of the formulations, evaluation of their permeability through an in vitro BBB model, and assessment of their activity on disease-representative cellular models, such as Alzheimer's disease and amyotrophic lateral sclerosis, have been conducted. The results demonstrate the potential of the new MTLs and their nanoparticle encapsulation for the treatment of neurodegenerative diseases.

Apa Reference Nozal, V., Fernández-Gómez, P., García-Rubia, A., Martínez-González, L., Cuevas, E.P., Carro, E., Palomo, V. & Martínez, A. (2024). Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation. Biomedicine & Pharmacotherapy, 175, 116626. 10.1016/j.biopha.2024.116626
Doi 10.1016/j.biopha.2024.116626
Publication Date Jun 2024
Publication Type Article
Researcher Ana Martínez
Ontology Molecular Interactions/Docking
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home